Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505975 | 0.87 | MEN1 (0.58) | ABCG2CNR2MEN1KMT2AFAAH | |
| SCHEMBL6093635 | 0.86 | CNR2 (0.55) | CNR2MEN1KMT2ACYP1B1P2RX7 | |
| SCHEMBL5509233 | 0.83 | ABCG2 (0.52) | ABCG2MEN1KMT2A | |
| SCHEMBL4728510 | 0.78 | PKM (0.46) | ABCG2CNR2MEN1KMT2A | |
| SCHEMBL4729406 | 0.78 | PKM (0.46) | ABCG2CNR2MEN1KMT2A | |
| SCHEMBL5510873 | 0.78 | ABCG2 (0.56) | ABCG2MEN1KMT2AATMP2RX7 | |
| SCHEMBL4726956 | 0.77 | MEN1 (0.42) | CNR2MEN1KMT2AFAAHL3MBTL1 | |
| SCHEMBL4728653 | 0.76 | HPGDS (0.54) | — | |
| SCHEMBL4780927 | 0.76 | ALDH1A1 (0.46) | CYP1A1CYP1A2CYP1B1CYP2D6 | |
| SCHEMBL4731545 | 0.76 | ALDH1A1 (0.46) | CYP1A1CYP1A2CYP1B1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | claimed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | claimed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| EP-1804781-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | Merz Pharma GmbH & Co.KGaA (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006037996-A1 | NOVEL CYCLIC AND ACYCLIC PROPENONES FOR TREATING CNS DISORDERS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | ABCG2 3170/4885CNR2 4/4885MEN1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.